European Heart Journal · 2020 · 30 citations · 11 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyInterventional CardiologyAnticoagulant TherapyAnticoagulation ManagementAntiplatelet TherapyAtrial FibrillationCardiac PharmacotherapyCardiovascular Drug SafetyAcute Coronary Syndrome Antithrombotic TherapyAnticoagulation During Coronary InterventionAntiplatelet Therapy After Percutaneous Coronary InterventionChronic Coronary SyndromeP2y12 Receptor InhibitorsPercutaneous Coronary Intervention CarePost-percutaneous Coronary Intervention Antithrombotic TherapyVitamin K Antagonist Therapy
AIMS: To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). METHODS AND RESULTS: In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363, VKA = 366). Participants received edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months, or VKA combined with a P2Y12 inhibitor and aspirin 100 mg (for 1-12 months). The primary bleeding endpoint at 12 months occurred in 59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.59-1.02, P = 0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94, 95%CI: 0.68-1.31, P = 0.708) with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) = 0.2741]. The main secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic events, or definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70-1.92), compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47-1.78) CCS patients with edoxaban and VKA-based therapy, respectively (P-int = 0.5573). CONCLUSIONS: In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation.
11
Clinical End Points in Coronary Stent Trials
Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
C. Michael Gibson, Roxana Mehran, Christoph Bode et al. · New England Journal of Medicine · 2016 · 1.6K citations · Full text
A. Pieter Kappetein, Stuart J. Head, Philippe Généreux et al. · European Heart Journal · 2012 · 1K citations · Full text
Medicine, Cardiology, Surgery +17